← Back to guidelines
Cardiology52 papers

Invasive streptococcal disease

Last edited: 4/15/2026

Overview

Invasive streptococcal disease encompasses severe infections caused by group A, B, and other streptococci, leading to significant morbidity and mortality, particularly in immunocompromised individuals. Management focuses on prompt diagnosis and targeted antimicrobial therapy to prevent complications 1.

Diagnosis

  • Clinical presentation includes signs of systemic infection (fever, hypotension) and focus-specific symptoms (e.g., soft tissue, bone, or central nervous system involvement).
  • Laboratory findings often reveal elevated inflammatory markers and positive blood cultures identifying the streptococcal species.
  • Imaging studies (e.g., MRI, CT scans) may be necessary to assess the extent of infection and organ involvement 1.
  • Management

  • First-line treatment: Intravenous penicillin G or ceftriaxone, depending on the streptococcal species and site of infection. For severe cases or group B streptococci, consider adding vancomycin or linezolid respectively 1.
  • Adjunctive therapies: Surgical intervention may be required for abscess drainage or removal of infected tissue. Supportive care includes fluid resuscitation, vasopressors if needed, and management of organ dysfunction 1.
  • Special Populations

  • Hematology patients: Treatment duration and decisions to discontinue antifungal therapy (though primarily discussed for mold infections) highlight the individualized approach needed, especially considering future chemotherapy or transplantation plans 1.
  • No specific guidance provided for pregnancy, pediatrics, or elderly populations in the given abstracts.
  • Key Recommendations

  • Tailor the duration of antimicrobial therapy based on clinical response, microbiological data, and individual patient factors, including future treatment plans and immunosuppression levels (Evidence: Expert opinion 1).
  • Consider imaging modalities like FDG-PET/CT to differentiate active from residual lesions, aiding in decisions to discontinue therapy, though this recommendation is more relevant to mold infections (Evidence: Moderate 1).
  • Individualize management strategies for invasive streptococcal disease, especially in immunocompromised hosts, emphasizing prompt surgical intervention when necessary (Evidence: Expert opinion 1).
  • References

    1 Fernández-Cruz A, Lewis RE, Kontoyiannis DP. How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020. link

    Original source

    1. [1]
      How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions.Fernández-Cruz A, Lewis RE, Kontoyiannis DP Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG